Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 78.56 B
The data is delayed by 15 minutes.
Description: Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The company?s commercial stage products include REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; and POMALYST/IMNOVID for the treatment of multiple myeloma. Its commercial stage products also comprise THALOMID for the patients with multiple myeloma and for the acute treatment of the cutaneous manifestations of erythema nodosum leprosum; ISTODAX to treat cutaneous T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. The company?s
|Shares Outstanding||774.6 M||EPS||3.09||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||14.91%||Sales Growth - Q/Q||9.47%||P/E||39.6|
|P/E To EPS Growth||P/S||9.32||P/BV||12.43||Price/Cash Per Share||10.49|
|Price/Free Cash Flow||29.58||ROA||12.38%||ROE||34.76%||ROI||15.22%|
|Current Ratio||3.34||Quick Ratio||3.2||Long Term Debt/Equity||0.9||Debt Ratio||0.47|
|Gross Margin||95.19%||Operating Margin||31.72%||Net Profit Margin||26.08%||Dividend Payout Ratio|
|Cash From Financing Activities||-951.3 M||Cash From Investing Activities||239.7 M||Cash From Operating Activities||1.14 B||Gross Profit||2.18 B|
|Net Profit||356.2 M||Operating Profit||412.4 M||Total Assets||17.75 B||Total Current Assets||9.88 B|
|Total Current Liabilities||2.96 B||Total Debt||7.62 B||Total Liabilities||11.42 B||Total Revenue||2.28 B|
|High 52 week||96.88||Low 52 week||59.21||Last close||95.42||Last change||-0.09%|
|RSI||55.66||Average true range||1.1||Beta||1.07||Volume||2.51 M|
|Simple moving average 20 days||0.58%||Simple moving average 50 days||3.1%||Simple moving average 200 days||12.36%|
|Performance Week||-0.09%||Performance Month||1.19%||Performance Quart||5.22%||Performance Half||35.85%|
|Performance Year||17.28%||Performance Year-to-date||48.88%||Volatility daily||0.69%||Volatility weekly||1.54%|
|Volatility monthly||3.16%||Volatility yearly||10.94%||Relative Volume||218.43%||Average Volume||8.89 M|
|New High||New Low|
2019-06-26 17:40:00 | The 2 Biggest Casualties From the Celgene-Bristol-Myers Merger So Far
2019-06-26 11:00:29 | Big Pharma Has to Bet Big on M&A. Investors Don’t.
2019-06-26 11:00:03 | AbbVie to Buy Allergan: Prescribed ETFs
2019-06-26 09:26:01 | AbbVie to Acquire Allergan in Nearly $62B Cash & Stock Deal
2019-06-26 09:22:01 | The Zacks Analyst Blog Highlights: AbbVie, Allergan, Bristol-Myers and Celgene
2019-06-25 16:15:08 | AbbVie + Allergan: Where Are The Synergies?
2019-06-25 15:56:07 | Bristol-Myers to Sell Otezla for Celgene Merger, Shares Down
2019-06-25 11:02:00 | The 10 Biggest Biotech Stocks
2019-06-25 10:11:02 | AbbVie Announces Lifting of FDA's Partial Hold on CANOVA Study
2019-06-25 09:35:01 | Company News For Jun 25, 2019
2019-06-24 20:06:30 | Traders Still Avoiding Small Caps
2019-06-24 16:55:57 | What Happened in the Stock Market Today
2019-06-24 16:29:19 | US STOCKS-S&P 500 slips as healthcare drags, investors eye G20 summit
2019-06-24 16:26:00 | Stocks End Mixed as Wall Street Looks to G-20 Summit for U.S.-China Trade Talks
2019-06-24 16:23:08 | Why These Innovative Biotech ETFs Soaring
2019-06-24 16:14:08 | Celgene Told To Divest Blockbuster Drug — And Other Bad News For Bristol
2019-06-24 15:51:06 | Bristol-Myers Squibb Company -- Moody's: Bristol's Otezla divestiture credit negative
2019-06-24 15:47:34 | 5 Top Stock Trades for Tuesday: CELG, BMY, CZR
2019-06-24 15:17:23 | Bristol-Myers tumbles as its $74 billion merger with Celgene faces setback
2019-06-24 14:27:39 | US STOCKS-Wall Street struggles for direction ahead of G20 summit
2019-06-24 13:12:37 | US STOCKS-Wall St flat as healthcare losses limit tech gains
2019-06-24 12:03:18 | Bristol-Myers Will Divest Celgene Blockbuster to Close Deal
2019-06-24 11:29:40 | US STOCKS-Wall St edges higher as tech gains more than offset healthcare losses
2019-06-24 10:56:08 | Bristol-Myers plans to divest Celgene's psoriasis drug
2019-06-24 10:52:00 | Bristol-Myers Plans Otezla Sale to Win FTC Approval for $74 Billion Celgene Deal
2019-06-24 10:39:18 | US STOCKS-Wall Street edges higher as tech offsets healthcare loss
2019-06-24 10:04:58 | To allay FTC concerns, Bristol-Myers to sell Celgene psoriasis treatment
2019-06-24 09:00:00 | Bristol-Myers Squibb Stock Is Falling as Celgene Deal Is Delayed
2019-06-21 10:01:02 | 3 Big Biotechs Hold Growth Potential in Second Half of 2019
2019-06-21 09:15:01 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?
2019-06-21 08:53:12 | 5 Best-Performing S&P 500 Stocks So Far This Year
2019-06-21 08:00:00 | Where Will bluebird bio Be in 1 Year?
2019-06-20 17:00:00 | 3 Drugs Under FDA Review With Blockbuster Potential
2019-06-20 09:05:00 | What Should Celgene's Investors Do With Everything Bristol-Meyer Squibb Is Giving Them?
2019-06-19 17:45:00 | This would be the worst-case scenario for health companies, according to UBS
2019-06-19 16:07:08 | Alexion's ALXN Ultomiris Gets Approval in Japan for PNH
2019-06-19 12:02:04 | Zacks.com featured highlights include: Citigroup, DSW, Celgene and Zions
2019-06-19 09:06:01 | Big Drugmakers That May Tread the M&A Path After Pfizer
2019-06-18 09:25:01 | Celgene CELG Hits 52-Week High, Can the Run Continue?
2019-06-18 08:55:12 | 4 High Earnings Yield Stocks to Strengthen Your Portfolio
2019-06-18 08:05:44 | See what the IHS Markit Score report has to say about Celgene Corp.
2019-06-17 15:41:07 | Novartis NVS Announces Promising Data on Tasigna & Hyrimoz
2019-06-17 09:12:01 | Regeneron REGN Presents Positive Data on Lymphoma Candidate
2019-06-16 09:00:00 | Is It Too Late to Buy Celgene Stock?
2019-06-14 08:29:12 | Mallinckrodt Presents Encouraging Data on Acthar Gel for RA